GFCAS12 Trademark

Trademark Overview


On Tuesday, April 7, 2020, a trademark application was filed for GFCAS12 with the United States Patent and Trademark Office. The USPTO has given the GFCAS12 trademark a serial number of 88862249. The federal status of this trademark filing is REGISTERED as of Tuesday, May 11, 2021. This trademark is owned by G+FLAS Life Sciences, Inc.. The GFCAS12 trademark is filed in the Pharmaceutical Products category with the following description:

Veterinary diagnostic reagents for use in veterinary genetic testing; Diagnostic preparations for veterinary purposes; Enzymes for medical purposes for genome editing-based therapy; Genome editing-based treatment preparations in the nature of preparations for detecting mutation in genes for medical purposes; Protein arrays for medical diagnostic purposes; Biological preparations for the treatment of cancers, rheumatoid arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, psoriasis, diabetes, multiple sclerosis, heart attack, systemic lupus erythematous, age-related macular degeneration, diabetic retinopathy, prevention of pneumonia, anemia, chronic migraine, hepatitis B, hemophilia, respiratory syncytial virus (RSV) prophylaxis, HPV prevention, varicella virus vaccine, growth hormone deficiency, osteoporosis, allergic asthma, chronic idiopathic urticaria, infertility, prevention of meningococcal disease, cystic fibrosis, paroxysmal nocturnal hemoglobinuria, autoimmun...
gfcas12

General Information


Serial Number88862249
Word MarkGFCAS12
Filing DateTuesday, April 7, 2020
Status700 - REGISTERED
Status DateTuesday, May 11, 2021
Registration Number6344786
Registration DateTuesday, May 11, 2021
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, February 23, 2021

Trademark Statements


Goods and ServicesVeterinary diagnostic reagents for use in veterinary genetic testing; Diagnostic preparations for veterinary purposes; Enzymes for medical purposes for genome editing-based therapy; Genome editing-based treatment preparations in the nature of preparations for detecting mutation in genes for medical purposes; Protein arrays for medical diagnostic purposes; Biological preparations for the treatment of cancers, rheumatoid arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, psoriasis, diabetes, multiple sclerosis, heart attack, systemic lupus erythematous, age-related macular degeneration, diabetic retinopathy, prevention of pneumonia, anemia, chronic migraine, hepatitis B, hemophilia, respiratory syncytial virus (RSV) prophylaxis, HPV prevention, varicella virus vaccine, growth hormone deficiency, osteoporosis, allergic asthma, chronic idiopathic urticaria, infertility, prevention of meningococcal disease, cystic fibrosis, paroxysmal nocturnal hemoglobinuria, autoimmune diseases infectious diseases for medical or veterinary purposes; Cultures of microorganisms for medical purposes; Cells for medical purposes; Reagents for use in medical genetic testing; Stem cells for medical purposes; Diagnostic preparations for medical purposes; Medicinal protein in the nature of protein arrays for medical diagnostic purposes; Medicinal enzymes; Medicines for human purposes and medicines for animals in the nature of medicines for cancers, rheumatoid arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, psoriasis, diabetes, multiple sclerosis, heart attack, systemic lupus erythematous, age-related macular degeneration, diabetic retinopathy, prevention of pneumonia, anemia, chronic migraine, hepatitis B, hemophilia, respiratory syncytial virus (RSV) prophylaxis, HPV prevention, varicella virus vaccine, growth hormone deficiency, osteoporosis, allergic asthma, chronic idiopathic urticaria, infertility, prevention of meningococcal disease, cystic fibrosis, paroxysmal nocturnal hemoglobinuria, autoimmune diseases, infectious diseases; Surgical implants grown from stem cells in the nature of surgical implants comprised of living tissue; Pharmaceutical preparations for genome editing-based therapy of rare inherited disorders; Ferments for medical or veterinary use; Preparations for detecting mutation in genes for medical purposes; Nucleic acid sequences for medical and veterinary purposes; Enzymes for medical purposes
Pseudo MarkGFCAS TWELVE; GFCAS ONE TWO

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, April 14, 2020
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameG+FLAS Life Sciences, Inc.
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressSeoul 08790
KR

Party NameG+FLAS Life Sciences, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressSeoul 08790
KR

Party NameG+FLAS Life Sciences, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressSeoul 08790
KR

Trademark Events


Event DateEvent Description
Tuesday, May 11, 2021REGISTERED-PRINCIPAL REGISTER
Tuesday, February 23, 2021OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, February 23, 2021PUBLISHED FOR OPPOSITION
Wednesday, February 3, 2021NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Saturday, January 16, 2021APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, December 29, 2020TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, December 28, 2020CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, December 28, 2020TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, July 2, 2020NOTIFICATION OF NON-FINAL ACTION E-MAILED
Thursday, July 2, 2020NON-FINAL ACTION E-MAILED
Thursday, July 2, 2020NON-FINAL ACTION WRITTEN
Thursday, June 25, 2020ASSIGNED TO EXAMINER
Wednesday, May 13, 2020TEAS CHANGE OF CORRESPONDENCE RECEIVED
Wednesday, May 13, 2020TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Wednesday, May 13, 2020ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Wednesday, May 13, 2020TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Tuesday, April 14, 2020NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Friday, April 10, 2020NEW APPLICATION ENTERED IN TRAM